Lalaye, Grand Est, France
Pharmaceutical and radiopharmaceutical expert with 15 years experience in conventional pharmaceutical industry (research and development) and 27 years in Nuclear Medicine (diagnosis and therapy, research and development, business development, industrialization processes) with presently a major emphasis on the strategic and business development of radioactivity applications in healthcare (nuclear medicine, radiopharmaceuticals).
Senior Consultant in the field of medical applications using radiations, mainly in nuclear medicine (radiopharmaceuticals) and particle therapy (protontherapy) with a main focus on business development (evaluation, competition analysis, strategic development, pipeline management) and translational processes (industrialization processes, regulatory constraints, clinical development).
Founder and President of the Foundation Oncidium, for the promotion and development of therapy based on nuclear medicine drugs
Aiming at transforming Posifit (GIE Nancyclotep) in a large French CDMO for central access to radiotheranostics used in clinical trials as well as becoming a European radiolabeled manufacturing unit for future tracers/drugs on the market
MEDraysintell Medical Radiation Strategic Intelligence Experts Bringing value to Businesses and Investors! MEDraysintell was created in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in radiotherapy, particle therapy and nuclear medicine. We aim to form an international team of experts in the field of Medical Radiation to provide Strategic Intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the markets and the competitive environment, as well as the potential of mergers and acquisitions (M&A) and technology development. MEDraysintell wants to support in their decisional process manufacturers of radiopharmaceuticals or therapeutic radioisotopes, suppliers of equipment and software, as well as investors interested in this industry. www.medraysintell.com